2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2933

The Microvascular Niche Instructs Pathogenic T Cells in Medium and Large Vessel Vasculitis
Abstract Number: 1650

The Montreal Cognitive Assessment Questionnaire (MoCA): A Promising Screening Tool for Cognitive Dysfunction in SLE
Abstract Number: 2912

The Neural Correlates of Inflammation in RA: A Multi-Modal MRI Study
Abstract Number: 2064

The Nomenclature of Gout: A Content Analysis of Contemporary Medical Journals
Abstract Number: 1784

The Novel Anti-CD40 Monoclonal Antibody CFZ533 Shows Beneficial Effects in Patients with Primary Sjögren’s Syndrome: A Phase IIa Double-Blind, Placebo-Controlled Randomized Trial
Abstract Number: 1924

The Nuclear Receptor ROR-Alpha As a Key Checkpoint of Tissue Repair
Abstract Number: 518

The Occurrence of Shingles and the Effect of Zoster Vaccination with the Use of Methotrexate in Rheumatoid Arthritis Patients
Abstract Number: 494

The Oral Microbiome Is Altered in Patients with Rheumatoid Arthritis
Abstract Number: 1092

The Ottawa Biologics Safety and Screening Tool
Abstract Number: 67

The Oxygen Sensor PHD1 Is an Indispensable Regulator of Arthritis Development
Abstract Number: 2714

The Paracaspase MALT1 Plays a Central Role in the Pathogenesis of Rheumatoid Arthritis
Abstract Number: 1143

The Patient Education for Gout Patients Ameliorate the Patients’ Satisfaction and Serum Uric Acid Level
Abstract Number: 345

The Patient Experience of Musculoskeletal Imaging Tests for Investigation of Inflammatory Arthritis: A Mixed Methods Study
Abstract Number: 2779

The Patient Perspective on Bdmard Dose Reduction: A Mixed Methods Study
Abstract Number: 1738

The Pattern of Proinflamatory Cytokine Expression By CD4+ T Lymphocytes Segregates the Clinical Response to Methotrexate in Recently Diagnosed Rheumatoid Arthritis Patients

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].